Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...
The FDA has approved Keytruda in combination with pemetrexed and platinum chemotherapy, as first-line Tx of unresectable advanced or metastatic malignant pleural mesothelioma.
Merck & Co., Inc. MRK announced that the FDA had approved its blockbuster anti-PD-1 therapy, Keytruda (pembrolizumab), for a ...
The FDA approved pembrolizumab (Keytruda; Merck) with chemotherapy as a first-line treatment for advanced or metastatic malignant pleural mesothelioma (MPM) that cannot be removed with surgery. In ...
Pembrolizumab plus chemotherapy is now an approved frontline treatment for patients with unresectable advanced or metastatic ...
The FDA approved pembrolizumab plus pemetrexted and platinum chemotherapy for advanced or metastatic malignant pleural mesothelioma. The FDA approved frontline pembrolizumab (Keytruda) plus pemetrexed ...
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on ...
Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy ...
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
00001) were also observed with pembrolizumab plus chemotherapy vs ... with unresectable advanced or metastatic malignant pleural mesothelioma, a disease where prognoses are generally poor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback